A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Colorectal Cancer
Interventions
DRUG

pentamidine

one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.

Trial Locations (1)

H3T 1E2

Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Oncozyme Pharma Inc.

INDUSTRY